cilostazol has been researched along with Complication, Postoperative in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "to evaluate whether systemic administration of cilostazol reduces neointimal hyperplasia in iliac arteries of pigs submitted to balloon catheter angioplasty." | 7.81 | Effect of cilostazol on neointimal hyperplasia in iliac arteries of pigs after transluminal angioplasty. ( Longhi, JA; Pereira, AH, 2015) |
| "to evaluate whether systemic administration of cilostazol reduces neointimal hyperplasia in iliac arteries of pigs submitted to balloon catheter angioplasty." | 3.81 | Effect of cilostazol on neointimal hyperplasia in iliac arteries of pigs after transluminal angioplasty. ( Longhi, JA; Pereira, AH, 2015) |
| "Ratios of red thrombus to prosthetic graft area were 0." | 1.35 | Effects of cilostazol and k-134 on reconstructive surgery using prosthetic grafts in the abdominal aorta of beagle dogs. ( Inoue, Y; Iwai, T; Jibiki, M; Kudo, T; Sugano, N, 2008) |
| "Cilostazol is an effective antiplatelet agent with minimum side effects after elective, bailout, or primary stent implantation." | 1.30 | Antiplatelet treatment with cilostazol after stent implantation. ( Kojima, S; Kuramochi, M; Matsumoto, Y; Sugi, T; Yano, M; Yoshitomi, Y, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, D | 1 |
| Satow, T | 1 |
| Murao, K | 1 |
| Nishimura, K | 1 |
| Iihara, K | 1 |
| Bhogal, P | 1 |
| Brouwer, PA | 1 |
| Makalanda, HL | 1 |
| Longhi, JA | 1 |
| Pereira, AH | 1 |
| Kim, JY | 1 |
| Choi, YS | 1 |
| Kwon, A | 1 |
| Chung, WB | 1 |
| Park, CS | 1 |
| Kim, HY | 1 |
| Chang, K | 1 |
| Lee, MY | 1 |
| Chung, WS | 1 |
| Seung, KB | 1 |
| Inoue, T | 1 |
| Russell, TE | 1 |
| Kasper, GC | 1 |
| Seiwert, AJ | 1 |
| Comerota, AJ | 1 |
| Lurie, F | 1 |
| Nakagawa, I | 2 |
| Park, HS | 1 |
| Wada, T | 1 |
| Yokoyama, S | 1 |
| Yamada, S | 1 |
| Motoyama, Y | 1 |
| Kichikawa, K | 1 |
| Nakase, H | 1 |
| Inoue, Y | 1 |
| Sugano, N | 1 |
| Jibiki, M | 1 |
| Kudo, T | 1 |
| Iwai, T | 1 |
| Yoshimoto, T | 1 |
| Fujimoto, S | 1 |
| Muraki, M | 1 |
| Kobayashi, R | 1 |
| Yoshidumi, T | 1 |
| Yamauchi, T | 1 |
| Tokuda, K | 1 |
| Kaneko, S | 1 |
| Suh, JW | 1 |
| Lee, SP | 1 |
| Park, KW | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Chae, IH | 1 |
| Choi, DJ | 1 |
| Rha, SW | 1 |
| Bae, JH | 1 |
| Kwon, TG | 1 |
| Bae, JW | 1 |
| Cho, MC | 1 |
| Kim, HS | 1 |
| Kato, T | 1 |
| Sakai, H | 1 |
| Takagi, T | 1 |
| Nishimura, Y | 1 |
| Yoshitomi, Y | 1 |
| Kojima, S | 1 |
| Sugi, T | 1 |
| Yano, M | 1 |
| Matsumoto, Y | 1 |
| Kuramochi, M | 1 |
| Tanabe, Y | 1 |
| Ito, E | 1 |
| Suzuki, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
1 review available for cilostazol and Complication, Postoperative
| Article | Year |
|---|---|
Cilostazol: an antiplatelet agent for the neurointerventionist?
Topics: Cilostazol; Humans; Neurosurgical Procedures; Platelet Aggregation Inhibitors; Postoperative Complic | 2016 |
4 trials available for cilostazol and Complication, Postoperative
8 other studies available for cilostazol and Complication, Postoperative
| Article | Year |
|---|---|
Efficacy of cilostazol in prevention of bradycardia during carotid artery stenting.
Topics: Aged; Aged, 80 and over; Bradycardia; Carotid Arteries; Cilostazol; Female; Humans; Intraoperative C | 2014 |
Effect of cilostazol on neointimal hyperplasia in iliac arteries of pigs after transluminal angioplasty.
Topics: Angioplasty; Animals; Cilostazol; Hyperplasia; Iliac Artery; Neointima; Phosphodiesterase 3 Inhibito | 2015 |
It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Evero | 2015 |
[Cilostazol].
Topics: Cilostazol; Coronary Restenosis; Humans; Percutaneous Coronary Intervention; Phosphodiesterase 3 Inh | 2016 |
Cilostazol May Improve Maturation Rates and Durability of Vascular Access for Hemodialysis.
Topics: Aged; Arteriovenous Shunt, Surgical; Cardiovascular Agents; Case-Control Studies; Cilostazol; Drug A | 2017 |
Effects of cilostazol and k-134 on reconstructive surgery using prosthetic grafts in the abdominal aorta of beagle dogs.
Topics: Animals; Aorta, Abdominal; Blood Vessel Prosthesis Implantation; Cilostazol; Male; Mice; Plastic Sur | 2008 |
Antiplatelet treatment with cilostazol after stent implantation.
Topics: Aged; Cilostazol; Coronary Disease; Coronary Thrombosis; Evaluation Studies as Topic; Female; Follow | 1998 |
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Cilos | 2001 |